Advertisement

Psychopharmacology

, Volume 235, Issue 8, pp 2303–2314 | Cite as

Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis

  • Kenji Sakuma
  • Shinji Matsunaga
  • Ikuo Nomura
  • Makoto Okuya
  • Taro Kishi
  • Nakao Iwata
Original Investigation

Abstract

Rationale

This study aims to examine whether folate/folic acid/methylfolate/folinic acid supplemented to antipsychotics (FA + AP) is beneficial in schizophrenia treatment.

Objective

We conducted a comprehensive systematic review and meta-analysis of double-blind, placebo-controlled, randomized clinical trials (RCTs) of FA + AP for schizophrenia.

Methods

The primary outcome was an improvement in total symptoms. Other outcomes were psychopathology subscales (positive, negative, general, and depressive symptoms), discontinuation due to all-cause and adverse events, and individual adverse events. The meta-analysis evaluated the effect size based on a random-effects model.

Results

Although we included ten RCTs with 925 patients in total (seven folic acid RCTs (n = 789), two methylfolate RCTs (n = 96), and one folinic acid RCT (n = 40)) in the systematic review, only seven RCTs were included in the meta-analysis. Pooled FA + AP treatments were not superior to placebo + AP in the improvement of total (N = 7, n = 340; standardized mean difference (SMD) = − 0.20, 95% confidence interval (CI) = − 0.41, 0.02, p = 0.08, I2 = 0%), positive, general, or depressive symptoms. Pooled FA + AP treatments were more effective than placebo + AP for negative symptoms (N = 5, n = 281; SMD = −0.25, 95% CI = −0.49, −0.01, p = 0.04, I2 = 0%). Although pooled FA + AP treatments were associated with a lower incidence of serious adverse events than placebo treatments (N = 4, n = 241; risk ratio = 0.32, 95% CI = 0.12–0.82, p = 0.02, I2 = 0%; number needed to harm = not significant), there were no significant differences in other safety outcomes between both treatments.

Conclusions

Our findings suggest that pooled FA + AP treatment improves negative symptoms in schizophrenia patients. Moreover, this treatment was well tolerated. However, because our results might exhibit a small-study effect, future studies with a larger sample should be conducted to obtain more robust results.

Keywords

Folic acid Methylfolate Schizophrenia Systematic review Meta-analysis Negative symptoms 

Notes

Acknowledgments

We thank Dr. Donald C. Goff (Marvin Stern Professor, Vice Chair for Research, Department of Psychiatry, NYU Langone Medical Center, NY, USA), Dr. Eric A. Macklin (MGH Biostatistics Center, Boston, MA, USA), and Dr. William M. Greenberg (St. George’s University School of Medicine, True Blue, Grenada, Mental Health Association of Rockland County, Valley Cottage, NY, USA) for providing information for this study.

Author contributions

Dr. Sakuma had complete access to all the data used in the study and takes responsibility for the integrity of the data (with Drs. Matsunaga, Nomura, and Okuya) and accuracy of the data analysis (with Dr. Matsunaga and Dr. Kishi). The study concept and design were performed by Dr. Kishi. The manuscript was written by all authors. Dr. Iwata supervised the review.

Compliance with ethical standards

Competing interests

Drs. Sakuma, Matsunaga, Nomura and Okuya, Kishi, and Iwata declare that they have no direct conflicts of interest relevant to this study. No grant support or other sources of funding were used to conduct this study or prepare this manuscript. Dr. Sakuma has nothing to disclose. Dr. Nomura has received speaker’s honoraria from Meiji, MSD, and Otsuka. Dr. Okuya has received speaker’s honoraria from Meiji. Dr. Matsunaga has received speaker’s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Meiji, MSD, Novartis, Otsuka, and Tanabe-Mitsubishi and has received a Fujita Health University School of Medicine research grant and a grant-in-aid for Young Scientists (B). Dr. Kishi has received speaker’s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, MSD, and Tanabe-Mitsubishi (Yoshitomi) and has received a Health Labour Sciences Research Grant and a Fujita Health University School of Medicine research grant. Dr. Iwata has received speaker’s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has had research grants from GlaxoSmithKline, Meiji, and Otsuka.

Supplementary material

213_2018_4926_MOESM1_ESM.doc (360 kb)
ESM 1 (DOC 359 kb)

References

  1. Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784–788CrossRefPubMedGoogle Scholar
  2. Arroll MA, Wilder L, Neil J (2014) Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 13:91CrossRefPubMedPubMedCentralGoogle Scholar
  3. Brown HE, Roffman JL (2014) Vitamin supplementation in the treatment of schizophrenia. CNS Drugs 28:611–622CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cao B, Wang DF, Xu MY, Liu YQ, Yan LL, Wang JY, Lu QB (2016) Lower folate levels in schizophrenia: a meta-analysis. Psychiatry Res 245:1–7CrossRefPubMedGoogle Scholar
  5. Carney MW, Sheffield BF (1970) Associations of subnormal serum folate and vitamin B12 values and effects of replacement therapy. J Nerv Ment Dis 150:404–412CrossRefPubMedGoogle Scholar
  6. Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S (2017) Efficacy of 42 pharmacologic Cotreatment strategies added to antipsychotic Monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatr 74:675–684CrossRefGoogle Scholar
  7. Firth J, Stubbs B, Sarris J, Rosenbaum S, Teasdale S, Berk M, Yung AR (2017) The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. Psychol Med 47:1515–1527CrossRefPubMedGoogle Scholar
  8. Fleischhacker WW, Kemmler G (2007) The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology 32:2435–2436CrossRefPubMedGoogle Scholar
  9. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH (1990) Enhancement of recovery from psychiatric illness by methylfolate. Lancet 336:392–395CrossRefPubMedGoogle Scholar
  10. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161:1705–1708CrossRefPubMedGoogle Scholar
  11. Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). In: Collaboration TC (ed). http://handbookcochrane.org
  12. Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 127:41–45CrossRefPubMedGoogle Scholar
  13. ISRCTN32434568 (2009) OCTUMI-4: evaluation of mirtazapine and folic acid for schizophreniaGoogle Scholar
  14. Kane JM (2012) Treatment options for refractory positive and negative symptoms in schizophrenia. Schizophrenia research 136, S21Google Scholar
  15. Kay SR, Opler LA, Lindenmayer JP (1989) The Positive And Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl:59–67Google Scholar
  16. Krawiecka M, Goldberg D, Vaughan M (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 55:299–308CrossRefPubMedGoogle Scholar
  17. Lang FU, Kosters M, Lang S, Becker T, Jager M (2013) Psychopathological long-term outcome of schizophrenia -- a review. Acta Psychiatr Scand 127:173–182CrossRefPubMedGoogle Scholar
  18. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174:927–942CrossRefPubMedGoogle Scholar
  19. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH (2006) Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60:265–269CrossRefPubMedGoogle Scholar
  20. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94:5923–5928CrossRefPubMedPubMedCentralGoogle Scholar
  21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefPubMedPubMedCentralGoogle Scholar
  22. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11:143–149CrossRefPubMedGoogle Scholar
  23. NCT00202280 (2005) Efficacy of treating first episode psychosis with folic acid, B12 and B6 in addition to antipsychotic medication (Principal Investigator: Dr Colin P O'Donnel)Google Scholar
  24. NCT00300404 (2006) Effect of specific anti-toxoplasmatic add-on medcation in toxoplasma gondii seropositive individuals with schizophrenia or major depression. (Principal Investigator: Dunja Hinze-Selch)Google Scholar
  25. NCT00403247 (2006) Effect of high-dose B-complex vitamins on the symptoms of schizophrenia. (Principal Investigator: William M Greenberg)Google Scholar
  26. NCT01263080 (2010) Evaluation of mirtazapine and folic acid for schizophrenia: (RECOVERY2). (Principal Investigator: Gang Wang)Google Scholar
  27. Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131:185–196CrossRefPubMedGoogle Scholar
  28. Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, Tomotake M, Ohi K, Hashimoto R, Imoto I, Takeda M, Ohmori T (2014) Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 40:1154–1163CrossRefPubMedPubMedCentralGoogle Scholar
  29. Numata S, Kinoshita M, Tajima A, Nishi A, Imoto I, Ohmori T (2015) Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis. BMC Med Genet 16:54CrossRefPubMedPubMedCentralGoogle Scholar
  30. Rai V, Yadav U, Kumar P, Yadav SK, Gupta S (2017) Methylenetetrahydrofolate reductase A1298C genetic variant & risk of schizophrenia: A meta-analysis. Indian J Med Res 145(4): 437–447Google Scholar
  31. Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, Goff DC, Manoach DS (2008a) MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proc Natl Acad Sci U S A 105:17573–17578CrossRefPubMedPubMedCentralGoogle Scholar
  32. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC (2008b) Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 63:42–48CrossRefPubMedGoogle Scholar
  33. Roffman JL,Lamberti JS, Achtyes E, Macklin EA,GalendezGC, Raeke LH, Silverstein NJ, Tuinstra D, Hill M, Goff DC (2011) A multicenter investigation of folate plus B12 supplementation in schizophrenia. Neuropsychopharmacology 36, S198–S323Google Scholar
  34. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70:481–489CrossRefPubMedPubMedCentralGoogle Scholar
  35. Roffman JL,Lamberti JS, Achtyes E, Macklin EA,Galendez GC, Raeke LH, Tanner AS, Silverstein NJ, Ho NF, Smoller JW, Hill M, Goff DC (2014a) Effects of (6S)-5-methyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid supplementation on cortical thickness in schizophrenia. Neuropsychopharmacology 39, S6Google Scholar
  36. Roffman JL,Lamberti JS, Achtyes E, Macklin EA,GalendezGC, Raeke LH, Tanner AS, Silverstein NJ, Ho NF, Smoller JW, Hill M, Goff DC (2014b) Effects of folic acid and vitamin b12 supplementation on negative symptoms and related MRI indices. Schizophrenia Research 153, S80Google Scholar
  37. Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, Giegold M, Silverstein NJ, Bottiglieri T, Manoach DS, Smoller JW, Henderson DC, Goff DC (2017) Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry 23(2):316–322Google Scholar
  38. Rucklidge JJ, Kaplan BJ (2013) Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review. Expert Rev Neurother 13:49–73CrossRefPubMedGoogle Scholar
  39. Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53:1119–1129CrossRefPubMedGoogle Scholar
  40. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645CrossRefPubMedGoogle Scholar
  41. Wang WW, Wang XS, Zhang ZR, He JC, Xie CL (2017) A meta-analysis of folic acid in combination with anti-hypertension drugs in patients with hypertension and Hyperhomocysteinemia. Front Pharmacol 8:585CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychiatryFujita Health University School of MedicineToyoakeJapan
  2. 2.Department of Department of Geriatrics and Cognitive DisordersFujita Health University School of MedicineToyoakeJapan

Personalised recommendations